{"id":82542,"date":"2023-02-27T17:58:42","date_gmt":"2023-02-27T16:58:42","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/a-consortium-led-by-onechain-receives-e2-5-m-to-developan-innovative-car-t-therapy-against-leukemia\/"},"modified":"2024-04-24T13:22:01","modified_gmt":"2024-04-24T11:22:01","slug":"a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/","title":{"rendered":"A consortium led by OneChain receives \u20ac2.5 M to develop a new CAR-T therapy for leukaemia"},"content":{"rendered":"

An ambitious project led by OneChain Immunotherapeutics (OCI)<\/a>, based in the Barcelona Science Park, has received \u20ac2.5 M from the European Innovation Council, through EIC Transition<\/a> call, to develop of a new CAR-T therapy that does not require extraction of the patient’s own cells and simultaneously attacks two cancer cell targets. The treatment could benefit to 80% of patients with T-type acute lymphoblastic leukaemia (T-ALL), a subtype, mainly paediatric, that has few therapeutic options and accounts for 25% of all leukaemia cases.<\/strong><\/p>\n

CAR-T therapy consists of extracting the patient’s own lymphocytes (autologous), genetically modifying them to recognize and attack tumour cells, and reintroducing them into the body. Although this is an effective strategy that has revolutionized the treatment of many haematological cancers, the manufacturing process is long and costly. Moreover, in many cases, patients’ immune systems are impaired, and it is not possible to collect enough lymphocytes for the generation of CAR-T cells.<\/p>\n

The project lead by OCI, which will last three years, aims to develop this therapy to bring it into clinical practice, and will involve the Josep Carreras Leukaemia Research Institute, the Severo Ochoa Center for Molecular Biology (CBMSO, a joint research institute of the Spanish National Research Council and the Autonomous University of Madrid) and the Portuguese company iBET.<\/p>\n

Personalized therapy for more patients<\/strong><\/span><\/h3>\n

The therapy to be developed by\u00a0OCI will use a subtype of T cells, called gamma-delta, which are produced in the laboratory and are\u00a0allogeneic, meaning they will serve for any patient and eliminate donor dependency. “Our approach is based on the use of a type of T-cell that is not recognized by the patient’s immune system as foreign, making it a\u00a0universal therapy,” explains\u00a0Dr. Victor M. Diaz<\/strong>, OneChain’s research director and leader of the project. OCI already has a protocol for generating these cells and will now focus on refining it to\u00a0scale up this process to an industrial level, a task that will be undertaken by the Portuguese company iBET.<\/p>\n

“Generating these T cells in large quantities is going to be a challenge, but these types of therapies are the future,” says D\u00edaz<\/strong>. “Treatments as personalized as CAR-Ts, which only work for one person, are unfeasible in a public healthcare system. On the other hand,\u00a0if you have a universal therapy applicable to all types of patients, you reduce costs, the process is simpler, and you can treat the patient on demand,” he adds.<\/p>\n

Attacking the same cell from different sites<\/strong><\/span><\/h3>\n

Another innovative feature of the therapy is that it will simultaneously attack two targets present in cancer cells, making it more effective and broadening its therapeutic spectrum. CAR-T therapy is not yet an established option against T-cell leukaemias, such as T-ALL, since tumour T cells and healthy T cells have the same molecules on their surface. Therefore, CAR-Ts targeting T-ALL destroy both types of cells, causing severe immunosuppression in patients.<\/p>\n

OCI has already developed a CAR-T directed at the CD1a protein, a safe target which is hardly present in healthy tissues. However, this molecule is present in only 30% of T-ALL patients. “Our laboratory has determined\u00a0another marker, which will be combined with CD1a\u00a0to increase the treatment spectrum.\u00a0We hope to be able to treat up to 80% of patients\u00a0affected by this disease,\u00a0preserving their healthy cells,” highlights Dr. Pablo<\/strong>\u00a0Men\u00e9ndez,<\/strong> founder of OCI and director of the Stem Cell Biology, Developmental Leukaemia, and Immunotherapy Group at the Josep Carreras Leukaemia Research Institute.<\/p>\n

Attainment of his project is the result of a demanding selection process that has evaluated more than 180 proposals. The EIC has selected 34 of them with the aim of fostering transfer of scientific results to society. “EIC Transition projects seek to\u00a0mature and validate technologies\u00a0already proven in the lab to develop a business case and\u00a0bring them to the market,” concludes Diaz.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

An ambitious project led by OneChain Immunotherapeutics (OCI), based in the Barcelona Science Park, has received \u20ac2.5 M from the European Innovation Council, through EIC Transition call, to develop of…<\/p>\n","protected":false},"author":14,"featured_media":82537,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-82542","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business"],"acf":[],"yoast_head":"\nA consortium led by OneChain receives \u20ac2.5 M to develop a new CAR-T therapy for leukaemia - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A consortium led by OneChain receives \u20ac2.5 M to develop a new CAR-T therapy for leukaemia - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"An ambitious project led by OneChain Immunotherapeutics (OCI), based in the Barcelona Science Park, has received \u20ac2.5 M from the European Innovation Council, through EIC Transition call, to develop of...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-27T16:58:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-24T11:22:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/02\/OneChain-team.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"450\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"A consortium led by OneChain receives \u20ac2.5 M to develop a new CAR-T therapy for leukaemia\",\"datePublished\":\"2023-02-27T16:58:42+00:00\",\"dateModified\":\"2024-04-24T11:22:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\\\/\"},\"wordCount\":652,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/OneChain-team.jpeg\",\"articleSection\":[\"COMPANIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\\\/\",\"name\":\"A consortium led by OneChain receives \u20ac2.5 M to develop a new CAR-T therapy for leukaemia - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/OneChain-team.jpeg\",\"datePublished\":\"2023-02-27T16:58:42+00:00\",\"dateModified\":\"2024-04-24T11:22:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/OneChain-team.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/OneChain-team.jpeg\",\"width\":900,\"height\":450},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A consortium led by OneChain receives \u20ac2.5 M to develop a new CAR-T therapy for leukaemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A consortium led by OneChain receives \u20ac2.5 M to develop a new CAR-T therapy for leukaemia - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/","og_locale":"en_US","og_type":"article","og_title":"A consortium led by OneChain receives \u20ac2.5 M to develop a new CAR-T therapy for leukaemia - Parc Cient\u00edfic de Barcelona","og_description":"An ambitious project led by OneChain Immunotherapeutics (OCI), based in the Barcelona Science Park, has received \u20ac2.5 M from the European Innovation Council, through EIC Transition call, to develop of...","og_url":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2023-02-27T16:58:42+00:00","article_modified_time":"2024-04-24T11:22:01+00:00","og_image":[{"width":900,"height":450,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/02\/OneChain-team.jpeg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"A consortium led by OneChain receives \u20ac2.5 M to develop a new CAR-T therapy for leukaemia","datePublished":"2023-02-27T16:58:42+00:00","dateModified":"2024-04-24T11:22:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/"},"wordCount":652,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/02\/OneChain-team.jpeg","articleSection":["COMPANIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/","url":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/","name":"A consortium led by OneChain receives \u20ac2.5 M to develop a new CAR-T therapy for leukaemia - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/02\/OneChain-team.jpeg","datePublished":"2023-02-27T16:58:42+00:00","dateModified":"2024-04-24T11:22:01+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/02\/OneChain-team.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/02\/OneChain-team.jpeg","width":900,"height":450},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/a-consortium-led-by-onechain-receives-e2-5-m-to-develop-a-new-car-t-therapy-for-leukaemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"A consortium led by OneChain receives \u20ac2.5 M to develop a new CAR-T therapy for leukaemia"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/82542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=82542"}],"version-history":[{"count":6,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/82542\/revisions"}],"predecessor-version":[{"id":94837,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/82542\/revisions\/94837"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/82537"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=82542"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=82542"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=82542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}